Elevai Labs INC 8-K filings

PMGC Holdings Inc. completes the sale of its Elevai Skincare subsidiary to Carmell Corporation for a combination of stock, cash, and potential earn-out payments.

PMGC Holdings Inc. has successfully regained compliance with Nasdaq's bid price rule and has renamed two of its wholly-owned subsidiaries.

PMGC Holdings subsidiary, Elevai Biosciences, has terminated its CEO and appointed a new CEO and Chairman, effective January 8, 2025.

Carmell Corporation is set to acquire substantially all assets of Elevai Skincare for $1.075 million in stock, plus potential earnouts and cash payments.

PMGC Holdings Inc. reports the resignation of director Jordan R. Plews, effective December 23, 2024.

Elevai Labs Inc. has completed its reincorporation from a Delaware corporation to a Nevada corporation, now operating as PMGC Holdings Inc., effective December 20, 2024.

PMGC Holdings Inc., formerly Elevai Labs Inc., has dismissed TPS Thayer, LLC as its independent auditor and engaged HTL International, LLC, effective December 20, 2024.

Elevai Labs Inc. has completed a 1-for-200 reverse stock split of its common stock, effective November 27, 2024.

Elevai Labs Inc. has announced a 1-for-200 reverse stock split effective November 27, 2024, to comply with Nasdaq's minimum bid price requirement.

Elevai Labs Inc. has amended its bylaws to reduce the quorum requirement for shareholder meetings from a majority to one-third of the voting power.

Elevai Labs has enacted a 1-for-200 reverse stock split to comply with Nasdaq's minimum bid price requirement, effective November 27, 2024.

Elevai Labs has been granted an extension by Nasdaq to regain compliance with the minimum bid price rule, contingent on completing a reverse stock split and demonstrating compliance by January 9, 2025.

Elevai Labs Inc. has entered into second amended and restated consulting agreements with GB Capital Ltd and Northstrive Companies Inc. for its CEO and Non-Executive Chairman roles, respectively, outlining compensation and performance-based bonuses.

Elevai Biosciences, a subsidiary of Elevai Labs, has partnered with KCRN Research to support the development and submission of an Investigational New Drug (IND) application to the FDA for EL-22, a treatment for obesity and muscle loss.

Elevai Biosciences released positive preclinical data for EL-32, a dual-action blocker targeting myostatin and activin-A, showing potential for obesity treatment by preserving muscle mass while reducing fat.

Elevai Labs is appealing Nasdaq's delisting notice due to non-compliance with minimum bid price and stockholders' equity rules, despite a recent $8 million capital raise.

Elevai Labs has announced the pricing of an $8 million public offering consisting of common stock (or pre-funded warrants) and accompanying Series A and Series B warrants.

Elevai Labs has received a delisting notice from Nasdaq for failing to maintain a minimum bid price and adequate stockholders' equity, and intends to appeal the decision.

Elevai Labs showcased its innovative exosome-based hair loss treatment system at the National Hair Loss Medical Aesthetics conference, highlighting positive results from clinical applications.

Elevai Labs reports positive results from a clinical study of its Enfinity topical exosome serum, showing significant improvements in facial appearance.

Elevai Labs Inc. reports the resignation of Hatem Abou-Sayed MD as Chief Medical Officer and a member of the Board of Directors, effective August 1, 2024.

Elevai Labs Inc. has entered into a securities purchase agreement, raising $1.15 million through a private placement involving the sale of notes and shares to certain investors.

ELEVAI Labs is leveraging stem cell exosomes and mitochondrial biogenesis technology, discovered using AI, to develop advanced skincare and hair care products.

Elevai Labs and INmune Bio have amended their existing license agreement, modifying the payment schedule for the technology transfer fee.

Elevai Labs has announced the resignation of its CEO, the termination of two other executives, and the appointment of a new non-employee CEO and non-executive Chairman as part of a restructuring effort.

Elevai Labs Inc. has entered into a $200,000 unsecured revolving line of credit agreement with NorthStrive Fund II LLP, carrying a 20% annual interest rate.

Elevai Labs Inc. has received a notice from Nasdaq for failing to meet the minimum stockholders' equity requirement for continued listing, placing its stock at risk of delisting.

Elevai Labs has entered into a one-year consulting agreement with Santorio Biomedical, securing the services of Mr. Deniel Mero to advise on biotechnology opportunities and strategic matters.

Elevai Labs has obtained an exclusive global license, excluding South Korea, to develop and commercialize two engineered probiotic assets targeting muscle loss and obesity.

Elevai Labs received a delisting notice from Nasdaq due to its stock price falling below the minimum bid requirement and appointed a new chair to its compensation committee following a director's resignation.